Director Hoffman Ramps Up Annovis Shares, Buying 714K Amid Volatile Price Surge

Insider Buying Spikes Amid Volatile Share Price

The latest 4‑form filing shows that on April 2 2026, Hoffman Michael B purchased 713,800 shares of Annovis Bio at $2.10 per share, driving his post‑transaction holding to 3,288,539 shares. The transaction occurred just as the stock closed at $2.28, a 6.05 % weekly gain despite a steep 11.63 % monthly decline. The deal adds to a string of purchases made by Hoffman in the past year, most recently a $4.24 and $4.34 block on December 8, 2025. This pattern suggests a bullish stance, especially given that the company’s share price has rebounded from a 52‑week low of $1.11 to $2.28.

What This Means for Investors

Hoffman’s cumulative buy‑side activity—over 2.5 million shares since August 2025—signals confidence in Annovis’s drug development pipeline, notably its buntanetap program for neurodegenerative diseases. The recent purchase at a price well below the 52‑week high of $5.50 indicates that insiders still view the shares as undervalued relative to potential future milestones. For shareholders, the continued accumulation may provide a degree of stability in a stock that has struggled to maintain momentum amid regulatory and clinical uncertainties. However, the company’s negative P/E of –1.47 underscores the lack of earnings, meaning that insider purchases are more about future upside than current profitability.

Hoffman Michael B: A Buying Profile

Hoffman, a long‑time director, has consistently bought shares in relatively small increments—most transactions range from 5,000 to 975,610 shares—often at prices between $2.05 and $4.34. His activity peaks in periods of clinical progress or favorable press. Unlike some insiders who sell during market downturns, Hoffman has shown no significant sell‑side transactions in the last 12 months. The 223,357‑share holding held in a family trust further demonstrates a commitment to the company’s long‑term prospects.

Market Context and Social Media Buzz

The transaction’s timing aligns with a 24.94 % buzz spike on social platforms, though sentiment remains neutral. This heightened attention coincides with ongoing discussions about Annovis’s upcoming Phase 3 data release and the potential for a 2044 patent extension on buntanetap. While the share price has been volatile, the insiders’ buying activity and the company’s intellectual‑property milestones may temper short‑term volatility for risk‑tolerant investors.

Bottom Line

Insider purchases, especially by a director like Hoffman who has consistently bought rather than sold, are a positive signal for those betting on Annovis’s future therapeutic success. The current purchase reinforces a bullish narrative amid a stock that has recovered from a steep decline. Investors should weigh the company’s negative earnings against the potential upside of its drug pipeline and the strategic value of its recent patent gains.